- Home
- FGI vs APRE Comparison
FGI vs APRE Comparison
Compare FGI & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGI
- APRE
- Stock Information
- Founded
- FGI 1987
- APRE 2006
- Country
- FGI United States
- APRE United States
- Employees
- FGI N/A
- APRE N/A
- Industry
- FGI Industrial Specialties
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FGI Industrials
- APRE Health Care
- Exchange
- FGI Nasdaq
- APRE Nasdaq
- Market Cap
- FGI 7.2M
- APRE 8.4M
- IPO Year
- FGI 2022
- APRE 2019
- Fundamental
- Price
- FGI $0.51
- APRE $1.62
- Analyst Decision
- FGI
- APRE Strong Buy
- Analyst Count
- FGI 0
- APRE 2
- Target Price
- FGI N/A
- APRE $15.50
- AVG Volume (30 Days)
- FGI 84.8K
- APRE 29.8K
- Earning Date
- FGI 05-07-2025
- APRE 05-13-2025
- Dividend Yield
- FGI N/A
- APRE N/A
- EPS Growth
- FGI N/A
- APRE N/A
- EPS
- FGI N/A
- APRE N/A
- Revenue
- FGI $131,818,073.00
- APRE $1,502,581.00
- Revenue This Year
- FGI $8.04
- APRE N/A
- Revenue Next Year
- FGI $6.41
- APRE N/A
- P/E Ratio
- FGI N/A
- APRE N/A
- Revenue Growth
- FGI 12.43
- APRE 157.63
- 52 Week Low
- FGI $0.46
- APRE $1.41
- 52 Week High
- FGI $1.36
- APRE $5.90
- Technical
- Relative Strength Index (RSI)
- FGI 34.67
- APRE 36.93
- Support Level
- FGI $0.48
- APRE $1.41
- Resistance Level
- FGI $0.64
- APRE $1.59
- Average True Range (ATR)
- FGI 0.08
- APRE 0.11
- MACD
- FGI 0.00
- APRE 0.03
- Stochastic Oscillator
- FGI 18.35
- APRE 48.04
About FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. It offers sanitaryware, bath furniture, shower systems, customer kitchen cabinetry, and other accessory items. It is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. its revenue is generated by sanitaryware. Geographically it operates in the United States, Canada, Europe, Rest of the World, and the majority of its revenue comes from the United States.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.